ViroGates A/S

Equities

VIRO

DK0061030574

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 10:31:33 2024-05-02 am EDT			5-day change	1st Jan Change
6.2 ^DKK	-6.06%		-4.32%	+2.99%

Apr. 15	Virogates A/S Announces the Outcome of Its Q-Submission Filing for Sobi®? Turbi Latex with the Us Food and Drug Administration	CI
Mar. 21	ViroGates A/S Reports Earnings Results for the Full Year Ended December 31, 2023	CI

ViroGates gives notice to convene the Annual General Meeting on 25 April 2024

April 10, 2024 at 07:47 am EDT

10.4.2024 13:46:40 CEST | ViroGates | Notice to convene annual general meeting

COMPANY ANNOUNCEMENT - No. 2-2024 – Notice to convene the annual general assembly - 10 April 2024

BIRKERØD, DENMARK – ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, hereby convenes the Annual General Meeting on Thursday, 25 April 2024, at 5:00 pm.

The meeting will be at the company's address at Banevænget 13, 3460 Birkerød. The agenda, full proposals, and registration details can be found in the attached document and on the company’s website.

For further information, please contact:

ViroGates A/S:

CEO, Jakob Knudsen

Tel. (+45) 2226 1355, email: jk@virogates.com

Certified Advisor:

Västra Hamnen Corporate Finance

Per Lönn

Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se

About ViroGates

ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.

The company was founded in 2000. Headquartered in Denmark, ViroGates’ sales force covers the Nordics, Spain, and France, while distributors serve other markets. ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.

Disclosure regulation

Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.

Contacts

Jakob Knudsen, CEO, +45 2226 1355, jk@virogates.com

Attachments

20240410 -Company Announcement 2- ViroGates AGM 2024.pdf

Latest news about ViroGates A/S

Virogates A/S Announces the Outcome of Its Q-Submission Filing for Sobi®? Turbi Latex with the Us Food and Drug Administration	Apr. 15	CI
ViroGates A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
ViroGates A/S Provides Earnings Guidance for the Year 2024	Dec. 21	CI
ViroGates A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
ViroGates A/S Announces Positive Results from a Randomized Controlled Clinical Trial on Supar-Guided Antibody Treatment in Sepsis	23-09-22	CI
ViroGates A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-17	CI
Virogates Provides Earnings Guidance for 2023	23-08-17	CI
ViroGates A/S Announces an Agreement with Sobi for the Development of Suparnostic®	23-06-02	CI
ViroGates A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
ViroGates A/S Announces the Commercial Launch of suPARnostic POC+ Product	23-02-24	CI
ViroGates A/S Announces CE-IVD approval for suPARnostic® TurbiLatex on the Roche Diagnostics cobas® Pure and Pro instrument platforms	23-02-06	CI
Denmark's ViroGates Names New CFO	23-02-01	MT
ViroGates A/S Announces Chief Financial Officer Changes	23-02-01	CI
ViroGates A/S Revises Earnings Guidance for Full-Year 2022 and 2023	22-12-16	CI
ViroGates A/S Announces Executive Changes	22-12-06	CI
ViroGates A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
ViroGates A/S Announces the Publication of A New Study That Shows SsuPAR upar Causes Cardiovascular Disease	22-10-05	CI
ViroGates announces CE-IVD approval for suPARnostic® TurbiLatex on the Beckman Coulter AU5800 platform	22-09-23	CI
ViroGates A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-18	CI
ViroGates A/S Provides Revenue Guidance for the Year 2022 and 2023	22-06-22	CI
ViroGates A/S Announces Board Changes	22-05-30	CI
ViroGates Announces the CE-Ivd Accreditation of Its Finger-Prick Blood-Testing Product, Suparnostic® Poc+	22-05-25	CI
ViroGates A/S Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-04	CI
ViroGates A/S Announces Board Changes	22-04-28	CI
ViroGates A/S Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-23	CI

Chart ViroGates A/S

Duration

Period

More charts

Company Profile
ViroGates A/S is a Denmark-based medical technology company. Its develops a product line suPARnostic, which measures the amount of amount of soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The plasma level of suPAR reflects immune activation and is increased in such infectious diseases as HIV-1-infection, malaria, tuberculosis, Streptococcus pneumonia bacteraemia, sepsis, pneumococcal pneumonia and bacterial and viral CNS infection. Also, high suPAR levels are associated with increased inflammation, disease progression and risk of mortality. Thus, measuring suPAR levels serves as a marker to determine chances for survival upon hospital admission, as well as for monitoring for prevention of disease progression and earlier intervention time point. suPARnostic has two versions: Quantitative Point of Care Quick Triage test, which serves for patient triage in acute care, and Quantitative ELISA Assay that aims at clinical routine use.
Sector
Biotechnology & Medical Research
Calendar
2024-08-14 - Q2 2024 Earnings Release
More about the company

Income Statement Evolution
More financial data

Sector Bio Diagnostics & Testing
1st Jan change Capi.
VIROGATES A/S
+2.99% 6.09M
EXACT SCIENCES CORPORATION
-18.16% 11.03B
IOVANCE BIOTHERAPEUTICS, INC.
+58.43% 3.5B
GUARDANT HEALTH, INC.
-31.31% 2.23B
BGI GENOMICS CO., LTD.
-14.31% 2.16B
VERACYTE, INC.
-26.61% 1.54B
MARAVAI LIFESCIENCES HOLDINGS, INC.
+34.35% 1.12B
SEEGENE, INC.
-3.28% 737M
CAREDX, INC
-22.75% 477M
ADAPTIVE BIOTECHNOLOGIES CORPORATION
-40.20% 411M
Bio Diagnostics & Testing

	1st Jan change	Capi.
VIROGATES A/S	+2.99%	6.09M
EXACT SCIENCES CORPORATION	-18.16%	11.03B
IOVANCE BIOTHERAPEUTICS, INC.	+58.43%	3.5B
GUARDANT HEALTH, INC.	-31.31%	2.23B
BGI GENOMICS CO., LTD.	-14.31%	2.16B
VERACYTE, INC.	-26.61%	1.54B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+34.35%	1.12B
SEEGENE, INC.	-3.28%	737M
CAREDX, INC	-22.75%	477M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-40.20%	411M